Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi
Gate Card
Rewards
MRNA

Moderna Price

MRNA
$46.85
-$0.44(-0.93%)

*Data last updated: 2026-05-22 21:38 (UTC+8)

As of 2026-05-22 21:38, Moderna (MRNA) is priced at $46.85, with a total market cap of $18.75B, a P/E ratio of -4.06, and a dividend yield of 0.00%. Today, the stock price fluctuated between $46.77 and $48.32. The current price is 0.17% above the day's low and 3.04% below the day's high, with a trading volume of 4.70M. Over the past 52 weeks, MRNA has traded between $22.28 to $59.88, and the current price is -21.76% away from the 52-week high.

MRNA Key Stats

Yesterday's Close$48.12
Market Cap$18.75B
Volume4.70M
P/E Ratio-4.06
Dividend Yield (TTM)0.00%
Diluted EPS (TTM)8.09
Net Income (FY)-$2.82B
Revenue (FY)$1.94B
Earnings Date2026-07-31
EPS Estimate2.09
Revenue Estimate$101.09M
Shares Outstanding389.69M
Beta (1Y)1.056

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
SectorHealthcare
IndustryBiotechnology
CEOStéphane Bancel
HeadquartersCambridge,MA,US
Official Websitehttps://www.modernatx.com
Employees (FY)4.70K
Average Revenue (1Y)$413.61K
Net Income per Employee-$600.42K

Moderna (MRNA) FAQ

What's the stock price of Moderna (MRNA) today?

x
Moderna (MRNA) is currently trading at $46.85, with a 24h change of -0.93%. The 52-week trading range is $22.28–$59.88.

What are the 52-week high and low prices for Moderna (MRNA)?

x

What is the price-to-earnings (P/E) ratio of Moderna (MRNA)? What does it indicate?

x

What is the market cap of Moderna (MRNA)?

x

What is the most recent quarterly earnings per share (EPS) for Moderna (MRNA)?

x

Should you buy or sell Moderna (MRNA) now?

x

What factors can affect the stock price of Moderna (MRNA)?

x

How to buy Moderna (MRNA) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

MRNA
CFD
Trade

Hot Posts About Moderna (MRNA)

AngelEye

AngelEye

14 hours ago
#GateSquarePizzaDay #TradfiTradingChallenge 🔥 TradFi Setup Right Now Feels Like a Rotation Game — Not a Trend Chase Today’s TradFi list (USIDX, MU, MRNA, CVX, AMZN) actually tells a very clear story if you look at it through a trader’s lens — we’re not in a “one-direction market” right now, we’re in a sector rotation + macro uncertainty phase. USIDX is still the main driver in the background. Dollar strength keeps bouncing around because markets are constantly trying to price whether rate cuts are really coming soon or getting delayed again. When DXY stays sticky, equities don’t get clean breakouts — they chop and rotate. Looking at the equities: AMZN is still the “safe growth proxy” in this environment. It doesn’t move violently, but institutions keep using it as a liquidity parking zone. If risk sentiment improves, this is usually one of the first big caps to extend. CVX is interesting because energy is still tied directly to geopolitical risk. Any tension in oil supply keeps CVX bid, but it also makes it sensitive to sudden macro headlines. This is not a trending chart — it’s a news-reactive engine right now. MU is the most cyclical name here. Semiconductor sentiment is extremely sensitive to risk appetite. When liquidity is strong, MU runs hard. When macro tightens, it gets hit fast. Right now it’s basically a beta gauge for tech sentiment. MRNA is more of a defensive volatility play. It doesn’t follow the same macro rhythm — it moves on sector-specific catalysts and risk-off flows. Good for traders who like mean-reversion setups rather than trends. Overall, my takeaway is simple: We are not in a “buy everything” market. We are in a selective opportunity market where timing and sector choice matter more than direction bias. If I had to frame a trading idea, I’d say: 👉 Strength in AMZN + CVX on dips looks more sustainable 👉 MU needs confirmation before any aggressive long 👉 USIDX direction will decide whether this rotation continues or resets Right now I’m not forcing big positions — just watching for clean reaction zones and letting the market show intent first. What’s your take — are you trading this as a rotation market, or are you still holding directional bias on these names? ‍#TradFi交易分享挑战 #TradFi #Trading [@Gate广场_Official](gt://mention/ARAbClhcBQNwWRIVGAoGBB5QX1sO0O0O)
USIDX-0.31%
MU+1.91%
MRNA-0.72%
CVX+0.32%
6
13
0
0
Crypto_Buzz_with_Alex

Crypto_Buzz_with_Alex

15 hours ago
#TradfiTradingChallenge 🔥 TradFi Setup Right Now Feels Like a Rotation Game — Not a Trend Chase Today’s TradFi list (USIDX, MU, MRNA, CVX, AMZN) actually tells a very clear story if you look at it through a trader’s lens — we’re not in a “one-direction market” right now, we’re in a sector rotation + macro uncertainty phase. USIDX is still the main driver in the background. Dollar strength keeps bouncing around because markets are constantly trying to price whether rate cuts are really coming soon or getting delayed again. When DXY stays sticky, equities don’t get clean breakouts — they chop and rotate. Looking at the equities: AMZN is still the “safe growth proxy” in this environment. It doesn’t move violently, but institutions keep using it as a liquidity parking zone. If risk sentiment improves, this is usually one of the first big caps to extend. CVX is interesting because energy is still tied directly to geopolitical risk. Any tension in oil supply keeps CVX bid, but it also makes it sensitive to sudden macro headlines. This is not a trending chart — it’s a news-reactive engine right now. MU is the most cyclical name here. Semiconductor sentiment is extremely sensitive to risk appetite. When liquidity is strong, MU runs hard. When macro tightens, it gets hit fast. Right now it’s basically a beta gauge for tech sentiment. MRNA is more of a defensive volatility play. It doesn’t follow the same macro rhythm — it moves on sector-specific catalysts and risk-off flows. Good for traders who like mean-reversion setups rather than trends. Overall, my takeaway is simple: We are not in a “buy everything” market. We are in a selective opportunity market where timing and sector choice matter more than direction bias. If I had to frame a trading idea, I’d say: 👉 Strength in AMZN + CVX on dips looks more sustainable 👉 MU needs confirmation before any aggressive long 👉 USIDX direction will decide whether this rotation continues or resets Right now I’m not forcing big positions — just watching for clean reaction zones and letting the market show intent first. What’s your take — are you trading this as a rotation market, or are you still holding directional bias on these names? ‍#TradFi交易分享挑战 #TradFi #Trading [@Gate广场_Official](gt://mention/ARAbClhcBQNwWRIVGAoGBB5QX1sO0O0O)
USIDX-0.31%
MU+1.91%
MRNA-0.72%
CVX+0.32%
9
19
0
0
LittleGodOfWealthPlutus

LittleGodOfWealthPlutus

20 hours ago
#TradFi交易分享挑战 Deep Analysis of Moderna (MRNA) Stock Today 1. Market Trend On May 21, 2026, Moderna (MRNA) closed at $48.12, down 1.79% from the previous trading day. In pre-market trading on May 22, the stock price was $47.299, continuing the pullback trend, with intraday fluctuations between $46.48 and $47.93, showing a volume-contracted bearish candlestick pattern. Trend Characteristics: The price has fallen nearly 6% from the early May high of $50.15, forming a technical correction, failing to break through the $49 round number, indicating short-term bullish momentum weakening. Volume Changes: On May 21, trading volume was 4.79 million shares, with a turnover rate of 1.21%, near the 20-day average level. There was no panic selling, but also no clear buying support, and the market remains on the sidelines. Market Sentiment: Affected by capital rotation within the overall biotech sector, MRNA was profit-taken by some investors in the short term, but no systemic selling driven by fundamentals was observed. 2. Technical Indicator Signals Trend Structure: The price has broken below the 5-day and 10-day moving averages, trading below the 20-day moving average (around $48.80). The short-term trend has shifted to a bearish alignment, with moving averages signaling a pullback; The 52-week high of $1,045 and the current price show a large gap, but this correction is a normal technical retracement, not a long-term trend reversal. Momentum Indicators: RSI (14 days): Estimated around 52–55, in the neutral zone, not entering oversold territory, indicating downward momentum has not been fully released, but there is no upward inertia; MACD (12,26,9): The DIF and DEA lines form a death cross below zero, with the MACD histogram remaining negative and expanding in magnitude, indicating bearish momentum is accumulating, and the short-term trend is weak; Bollinger Bands: Price is near the middle band (about $48.50), with narrowing bandwidth and decreasing volatility, suggesting the market is entering a consolidation phase with direction awaiting clarification. Volume-Price Coordination: During the pullback, volume did not significantly increase, implying the selling pressure mainly comes from technical profit-taking rather than institutional exit, and the decline lacks fundamental support. 3. Key Support and Resistance Levels Support Levels: $47.20–$47.50: The recent low on May 21 and pre-market key psychological support zone, also the convergence point of the 20-day moving average and previous low-volume trading area; breaking below could open further downside space; $46.00–$46.50: Corresponds to the late April 2026 platform low, a consensus among institutions as the first strong support, with technical buy clustering. Resistance Levels: $48.50–$48.80: The overlap zone of the 20-day moving average and the May 15 high, a short-term rebound neckline; $49.50–$50.00: The dense area of early May highs, forming medium-term technical resistance, requiring volume increase and market sentiment recovery for a breakout. Note: The current market lacks a unified institutional consensus. The above ranges are inferred from price structure, moving average systems, and historical trading clusters, aligning with mainstream technical analysis logic. 4. Market Outlook Short-term (1–2 weeks): Mainly consolidation: Expect repeated tug-of-war within $46.50–$48.80, waiting for a directional trigger; Key trigger points: - If volume breaks above $48.80, it may restart an upward channel targeting $50; - If it falls below $46.00, it could test the $44.00–$45.00 zone, forming a medium-term correction. Medium-term (1–3 months): Core drivers: - Tumor vaccine progress: Phase III data for MRNA-4157 (personalized mRNA tumor vaccine) combined with Keytruda will be released in Q3 2026. If showing significant survival benefits, it could trigger a valuation re-rating; - RSV vaccine commercialization: Global demand for RSV vaccines continues to grow in 2026, with MRNA as a major supplier, likely contributing stable cash flow; - Delivery system breakthroughs: The company is advancing extratumoral targeting LNP technology. Clinical breakthroughs in rare disease treatments could open a market worth hundreds of billions. Risks: If clinical data underperform or the FDA tightens mRNA vaccine approvals, short-term valuation may decline; If the Federal Reserve delays rate cuts, high-growth biotech stocks could face valuation pressure. Long-term Logic: - Continuous realization of mRNA platform value: MRNA has transitioned from relying solely on COVID-19 vaccines to a multi-indication platform covering tumors, infectious diseases, and rare diseases; - Strong technological moat: Its LNP delivery system, self-amplifying mRNA technology, and rapid iteration capabilities form barriers difficult to replicate; - Rigid global demand growth: Industry forecasts suggest the global mRNA therapy market will reach $42.6 billion by 2033, with a CAGR over 8%, with MRNA as one of the biggest beneficiaries. 5. Investment Recommendations Short-term traders: Try small positions within $47.20–$47.50, with stop-loss below $46.00; If volume breaks above $48.80, add positions aiming for $49.50–$50.00; Avoid chasing high in unvolume rebounds and beware of false breakouts. Medium- to long-term investors: $46.00–$47.00 is an ideal accumulation zone, can be bought in parts; Holding logic: Bet on the Phase III tumor vaccine data and delivery technology breakthroughs, with a cycle of 6–12 months; Consider options strategies (e.g., buying puts to hedge downside risk) to enhance position stability. $MRNA
MRNA-0.72%
5
6
0
0